NCT06561542
A Phase I Study of LX22001 for Injection in Healthy Subjects
StatusCompleted
PhasePhase 1
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 23 words Show 5 more changesShow less
- Trial status changed: Unknown → Completed
- Final enrollment: 100 participants (planned 70)
- Primary completion date changed from estimate of Nov 21, 2025 to Jan 23, 2025
- Secondary endpoints: details revised at 1 of 11 entries
- Site details revised
- Minor Changed Registry marked status Unknown; last known: Recruiting
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants With Adverse Events
Timeframe: 7 days from dosing
Secondary (11)
Area Under the Concentration-Time Curve From Time 0 to the 24-Hour Time Point (AUC0-24)
Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf)
Maximum Observed Plasma Concentration (Cmax)
Terminal elimination half-life(t1/2)
Apparent total body clearance (CL)
Show 6 moreShow less
Apparent volume of distribution(Vd)
Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) at Steady State
Cmax at Steady State (Cmax,ss)
Percentage of Time Gastric pH above 4 over 24h
Percentage of Time Gastric pH above 6 over 24h
Mean Gastric pH over 24h
Arms and interventions
LX22001 for InjectonExperimental
Tegoprazan tabletActive comparator
Esomeprazole sodium for injectionActive comparator
Drugs: LX22001 for Injeciton, Tegoprazan tablet, Esomeprazole sodium for injection
Sites
1 site in 1 country
- Peking Union Medical College Hospital, Chinese Academy of Medical SciencesBeijing, Beijing Municipality, China